Literature DB >> 16630020

Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy.

Michael P Weekes1, Mark R Wills, J G Patrick Sissons, Andrew J Carmichael.   

Abstract

Cytotoxic T-lymphocytes (CTL) play an important role in the control of human immunodeficiency virus (HIV) and of human cytomegalovirus (HCMV) infection. Following highly active antiretroviral therapy (HAART), most studies have demonstrated a decline in the frequency of HIV-specific CTL. We analysed the effect of HAART on the size, phenotype and function of individual HIV- and HCMV-specific CTL clones, using clonotypic oligonucleotide probing specific for the T-cell receptor (TCR) beta-chain hypervariable sequence of defined immunodominant CTL clones specific for peptides of HIV or HCMV, and quantified the limiting dilution analysis frequencies of CTL precursors (CTLp) specific for the same viral peptides. We found that the clonal composition of CD8+ T cells specific for HIV gag and env epitopes was highly focused and did not change after HAART. Following HAART, there was progressive contraction of HIV-specific CD8+ clones, especially in the CD28- CD27- subpopulation--the remaining cells of contracting HIV-specific clones were predominantly CD28- CD27+ CD45RO(hi). We observed maintenance of strong functional HIV-specific CD8+ T-cell responses in limiting dilution analysis following HAART, indicating preferential loss of HIV-specific cells that have reduced cloning efficiency in vitro. Following HAART, we also observed selective expansion of HCMV-specific CD8+ clones. Most HCMV-specific CD8+ clones were predominantly CD28- CD27+/- CD45RA(hi) following HAART. In one subject, a Vbeta6.4+ clone specific for HCMV pp65 selectively expanded following HAART, without expansion of two other Vbeta6.4+ clones, indicating that individual clonotypes specific for the same peptide can show different kinetics and phenotypes in response to antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630020      PMCID: PMC1782266          DOI: 10.1111/j.1365-2567.2006.02334.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

2.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.

Authors:  M R Wills; A J Carmichael; K Mynard; X Jin; M P Weekes; B Plachter; J G Sissons
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins.

Authors:  Q J Zhang; R Gavioli; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

4.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

Review 5.  Virologic and immunologic events in primary HIV infection.

Authors:  G Pantaleo; C Graziosi; A S Fauci
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection.

Authors:  X Jin; M Wills; J G Sissons; A Carmichael
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis.

Authors:  S L Silins; S M Cross; S L Elliott; S J Pye; S R Burrows; J M Burrows; D J Moss; V P Argaet; I S Misko
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

9.  Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.

Authors:  S A Kalams; R P Johnson; A K Trocha; M J Dynan; H S Ngo; R T D'Aquila; J T Kurnick; B D Walker
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P Moss; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; A Hurley; M Markowitz; D D Ho; A J McMichael; D F Nixon
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  6 in total

1.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells.

Authors:  Tobias M Nowacki; Stefanie Kuerten; Wenji Zhang; Carey L Shive; Christian R Kreher; Bernhard O Boehm; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  Cell Immunol       Date:  2007-09-07       Impact factor: 4.868

3.  Antiviral therapy can reverse the development of immune senescence in elderly mice with latent cytomegalovirus infection.

Authors:  Mark Beswick; Annette Pachnio; Sarah N Lauder; Clive Sweet; Paul A Moss
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

4.  CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control.

Authors:  Beatriz Mothe; Anuska Llano; Javier Ibarrondo; Jennifer Zamarreño; Mattia Schiaulini; Cristina Miranda; Marta Ruiz-Riol; Christoph T Berger; M José Herrero; Eduard Palou; Montse Plana; Morgane Rolland; Ashok Khatri; David Heckerman; Florencia Pereyra; Bruce D Walker; David Weiner; Roger Paredes; Bonaventura Clotet; Barbara K Felber; George N Pavlakis; James I Mullins; Christian Brander
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

5.  Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8+ T-Cells From HIV+ Subjects Who Initiated cART at Different Time-Points After Acute Infection.

Authors:  Jimena Salido; María Julia Ruiz; César Trifone; María Inés Figueroa; María Paula Caruso; María Magdalena Gherardi; Omar Sued; Horacio Salomón; Natalia Laufer; Yanina Ghiglione; Gabriela Turk
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

6.  Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART.

Authors:  Jimena Salido; Alejandro Czernikier; César Trifone; María Laura Polo; María Inés Figueroa; Alejandra Urioste; Pedro Cahn; Omar Sued; Horacio Salomon; Natalia Laufer; Yanina Ghiglione; Gabriela Turk
Journal:  Pathog Immun       Date:  2021-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.